Prostate cancer detection by prostate-specific antigen-based screening in Japanese Hiroshima area shows early stage, low-grade, and low rate of cancer-specific death compared with clinical detection

Authors

  • Jun Teishima Department of Urology, Institute of Biomedical and Health Sciences, Integrated Health Sciences, Hiroshima University
  • Satoshi Maruyama Departmeny of Urology, Hiroshima General Hospital
  • Hideki Mochizuki Department of Urology, Miyoshi Prefectural Hospital
  • Kiyotaka Oka Department of Urology, Integrated Health Sciences, Institute of Biomedical and Health Sciences, Hiroshima University
  • Kenichiro Ikeda Department of Urology, Integrated Health Sciences, Institute of Biomedical and Health Sciences, Hiroshima University
  • Keisuke Goto Department of Urology, Integrated Health Sciences, Institute of Biomedical and Health Sciences, Hiroshima University
  • Hirotaka Nagamatsu Department of Urology, Integrated Health Sciences, Institute of Biomedical and Health Sciences, Hiroshima University
  • Keisuke Hieda Department of Urology, Integrated Health Sciences, Institute of Biomedical and Health Sciences, Hiroshima University
  • Koichi Shoji Department of Urology, Integrated Health Sciences, Institute of Biomedical and Health Sciences, Hiroshima University
  • Akio Matsubara Department of Urology, Integrated Health Sciences, Institute of Biomedical and Health Sciences, Hiroshima University

DOI:

https://doi.org/10.5489/cuaj.1715

Keywords:

Prostate-specific antigen, mass screening, prostate cancer

Abstract

Introduction: We investigate the effectiveness of prostate-specific antigen (PSA) screening for prostate cancer. We compare the characteristics of 2 sets of patients: (1) those in whom prostate cancer was detected via PSA screening (the PS group) and (2) those in whom prostate cancer was detected at the outpatient office (the non-PS group).

Methods: Between 2002 and 2010, prostate cancer was detected in 315 patients by PSA screening. Their age, initial PSA level, pathological findings in biopsy specimens, clinical stage, and prognosis were compared with those of 497 prostate cancer patients diagnosed at the outpatient office of the Department of Urology, Hiroshima University, in the same period.

Results: The rates of patients with initial PSA higher than 50 ng/mL, with a Gleason score of 8 or higher, and with clinical stage D were significantly lower in the PS group than those in the non-PS group. The 5-year overall survival and cancer-specific survival in the PS group was 91.3% and 98.2%, respectively; these results were significantly better than those in the non-PS group (86.4%, p = 0.0178, and 94.9%, p = 0.0112, respectively). A Cox hazard analysis showed that PSA screening was an independent predictive factor for cancer-specific survival.

Conclusions: Although our study is limited by its retrospective nature and small size, the present data indicate that prostate cancer detected in the PS group showed earlier stage, lower grade, and better prognosis than in the non-PS group.

Downloads

Download data is not yet available.

Downloads

Published

2014-05-21

How to Cite

Teishima, J., Maruyama, S., Mochizuki, H., Oka, K., Ikeda, K., Goto, K., Nagamatsu, H., Hieda, K., Shoji, K., & Matsubara, A. (2014). Prostate cancer detection by prostate-specific antigen-based screening in Japanese Hiroshima area shows early stage, low-grade, and low rate of cancer-specific death compared with clinical detection. Canadian Urological Association Journal, 8(5-6), e327–32. https://doi.org/10.5489/cuaj.1715

Issue

Vol. 8 No. 5-6 (2014): CUAJ May

Section

Original Research

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.